Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Boryung Pharmaceuticals Co. Ltd.

www.boryung.co.kr/

Latest From Boryung Pharmaceuticals Co. Ltd.

Korean Pharma Accelerates Coronavirus-Related R&D, Calls For More Support

As South Korean companies jump into the development of vaccines and drugs for the coronavirus, they also call for stronger government support and increased collaboration between the state and private sectors.

South Korea Vaccines

Oncology, Diabetes Dominate Korean Out-Licensing But Deals And Value Decline

Scrip takes a look at how the South Korean pharma/biotech industry's cross-border deals over the past few years compare with global trends, finding that oncology and diabetes have been the dominant therapeutic areas for the out-licensing of assets, but recent activity and value have declined from a peak in 2015.

South Korea Commercial

Korea Stepping Up IO R&D To Catch Up With Global Players, Trends

Immuno-oncology deals and R&D by South Korean companies are picking up speed as they are put more focus on the hot sector in line with global trends.

Commercial ImmunoOncology

Deal Watch: Boehringer’s Hectic Stretch Adds Up To Five Deals

Following its partnership with Dicerna, the German pharma signs a second NASH deal with MiNA and inks three cancer-related transactions, including divestitures. Also, Amgen buys out Kirin’s half of their joint venture for $780m.

Deals M & A
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Cardiovascular
  • Gastrointestinal
  • Infectious & Viral Diseases
  • Metabolic Disorders
  • Neurology, Nervous System
  • Renal System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Asia
      • Pacific Rim
        • South Korea
  • Parent & Subsidiaries
  • Boryung Pharmaceuticals Co. Ltd.
  • Senior Management
  • Tae-Hong Choi, CEO
  • Contact Info
  • Boryung Pharmaceuticals Co. Ltd.
    Phone: (82)
    Cheonggyeonggung-ro 136
    Jongro-gu
    Seoul, 110-750
    South Korea
UsernamePublicRestriction

Register